Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNLX Genelux	$3.33 -2.1%	$2.83	$1.60 ▼ $5.89	$125.74M	-0.34	173,502 shs	45,235 shs
KRRO Korro Bio	$13.67 -1.2%	$13.38	$10.29 ▼ $98.00	$128.37M	2.43	109,000 shs	99,678 shs
NKTX Nkarta	$1.91 -4.5%	$1.81	$1.31 ▼ $7.24	$135.53M	0.7	1.02 million shs	1.05 million shs
RNTX Rein Therapeutics	$1.42 +1.4%	$1.76	$1.33 ▼ $4.40	$31.46M	1.22	36,467 shs	10,360 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNLX Genelux	-2.06%	-2.92%	+14.04%	+26.62%	+35.92%
KRRO Korro Bio	-1.16%	+7.55%	+9.71%	-1.65%	-71.73%
NKTX Nkarta	-4.50%	+4.37%	+4.95%	+5.52%	-74.77%
RNTX Rein Therapeutics	+1.43%	-1.39%	-13.41%	-16.47%	+141,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNLX Genelux	1.2612 of 5 stars	3.6	0.0	0.0	0.0	2.7	0.0	0.0
KRRO Korro Bio	1.8216 of 5 stars	3.6	1.0	0.0	0.0	2.7	0.0	0.6
NKTX Nkarta	2.1025 of 5 stars	3.6	0.0	0.0	0.0	3.2	1.7	0.6
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNLX Genelux	3.20	Buy	$17.75	433.03% Upside
KRRO Korro Bio	3.29	Buy	$102.43	649.29% Upside
NKTX Nkarta	3.13	Buy	$14.33	650.44% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RNTX, GNLX, NKTX, and KRRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Speculative Buy ➝ Speculative Buy	$25.00 ➝ $23.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNLX Genelux	$10K	12,574.08	N/A	N/A	$0.76 per share	4.38
KRRO Korro Bio	$2.27M	56.55	N/A	N/A	$17.12 per share	0.80
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.45 per share	3.17	$0.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNLX Genelux	-$29.87M	-$0.88	N/A	N/A	N/A	N/A	-93.04%	-74.17%	8/13/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A

Latest RNTX, GNLX, NKTX, and KRRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	GNLX Genelux	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	KRRO Korro Bio	-$2.54	N/A	N/A	N/A	$0.41 million	N/A
8/12/2025	Q2 2025	NKTX Nkarta	-$0.37	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNLX Genelux	N/A	4.67	4.67
KRRO Korro Bio	N/A	9.41	9.41
NKTX Nkarta	N/A	14.48	14.48
RNTX Rein Therapeutics	N/A	1.39	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNLX Genelux	37.33%
KRRO Korro Bio	13.18%
NKTX Nkarta	80.54%
RNTX Rein Therapeutics	90.89%

Insider Ownership

Company	Insider Ownership
GNLX Genelux	9.30%
KRRO Korro Bio	4.60%
NKTX Nkarta	8.40%
RNTX Rein Therapeutics	5.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNLX Genelux	10	37.76 million	34.25 million	Not Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
RNTX Rein Therapeutics	9	22.15 million	21.02 million	N/A

RNTX, GNLX, NKTX, and KRRO Headlines

Recent News About These Companies

RNTX - Rein Therapeutics Inc Dividends - Morningstar

June 26, 2025 | morningstar.comM

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

June 24, 2025 | prnewswire.com

US FDA puts on hold Rein Therapeutics' lung disease drug trial

June 12, 2025 | reuters.com

RNTX Rein Therapeutics Inc.

June 1, 2025 | seekingalpha.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | finanznachrichten.de

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025 | prnewswire.com

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025 | prnewswire.com

Rein Therapeutics, Inc.: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 16, 2025 | finanznachrichten.de

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | prnewswire.com

Rein Therapeutics begins trial for idiopathic pulmonary fibrosis treatment

May 13, 2025 | msn.com

Rein Therapeutics, Inc.: Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | finanznachrichten.de

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025 | prnewswire.com

Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment

May 2, 2025 | msn.com

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025 | prnewswire.com

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

April 30, 2025 | prnewswire.com

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

April 28, 2025 | prnewswire.com

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

April 23, 2025 | prnewswire.com

Rein Therapeutics reports IPF and PASC-F treatment progress

April 17, 2025 | uk.investing.com

Rein Therapeutics’ LTI-2355 peptide shows therapuetic potential in study

April 16, 2025 | markets.businessinsider.com

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

April 15, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX, GNLX, NKTX, and KRRO Company Descriptions

Genelux NASDAQ:GNLX

$3.33 -0.07 (-2.06%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.34 +0.01 (+0.30%)

As of 07/18/2025 06:25 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Korro Bio NASDAQ:KRRO

$13.67 -0.16 (-1.16%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$13.72 +0.05 (+0.40%)

As of 07/18/2025 04:04 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Nkarta NASDAQ:NKTX

$1.91 -0.09 (-4.50%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.94 +0.03 (+1.31%)

As of 07/18/2025 07:54 PM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Rein Therapeutics NASDAQ:RNTX

$1.42 +0.02 (+1.43%)

As of 07/18/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time